 |
|
Dr Stephen Little
Dr. Steve Little is one of the cofounders of DxS and has led the company since its formation in 2001. He has over 20 years' experience in the biotechnology industry and was previously a board and executive team member during 11 years at AstraZeneca Diagnostics. He has held management positions in both the pharmaceutical and diagnostic industries and has extensive experience in the development of nucleic acid based diagnostic products and services for human genetic analysis.
|
| |
|
|
|
|
Dr David Whitcombe
Dr. David Whitcombe was with AstraZeneca Diagnostics for 5 years where he headed the technology development group. He was the inventor of the Scorpions system and led the development of the key technologies used by DxS. He has over 15 years experience in genetic research and development.
|
| |
|
|
|
|
Andrew Webb
Andrew Webb was with Amersham Pharmacia Biotech for 11 years most recently as sales director responsible for licensing their proprietary technologies in genomics, proteomics and drug screening in Europe. He spent 5 years in drug metabolism at SmithKline Beecham prior to joining Amersham where his varied career encompassed key account management for customers in the pharmaceutical industry and subsequently sales management.
|
| |
|
|
|
|
Peter Collins
Peter Collins brings over 20 years of experience in the Diagnostics industry. He has served on the boards of a number of early stage companies in variety of commercial roles. He brings specific expertise in the area of Companion Diagnostics in the targeted Oncology market. At Vysis (Abbott Molecular Diagnostics) he was responsible for the strategy and delivery of the PathVysion Her 2 product used to select breast cancer patients eligible for Herceptin in Europe. Peter has also previously worked Syva, BD’s Immunocytometry Divison, Quantase Ltd, BioGenex, Pronostics and he joined DxS in March 2007.
|
| |
|
|
|
|
Derek Bannister
Derek qualified as a Chartered Accountant (KPMG) in 1980. He has been Finance Director of a variety of companies for over 20 years, working across various sectors including Marketing, Training and Pharma support companies. He was most recently involved in the MBO and subsequent very successful trade sale of Medeval, a Phase 1 clinical research organisation, based in Manchester. His experience has been gained mainly in SME’s helping these businesses maximise their potential and shareholder value.
|
| |
|
|
| |
|
|
Chris Bray
Chris Bray previously worked for Imutran Limited (A Novartis Pharma AG Company) and has over nine years experience working in Quality and Regulatory environments within the Healthcare Industry. He has a strong technical background and extensive experience in the auditing, design and implementation of Quality Systems.
|
| |
|
|
|
|
Paul Ravetto
Paul Ravetto has over ten years experience in genetic research and development. He trained at the Roslin Institute and prior to joining DxS held posts at the Institute of Ophthalmology and the University of Manchester, where he was investigating the genetics of childhood leukaemia. Paul has been with DxS since the company was founded during which time he has played a key role in both the development and running of the service laboratory as well as the development of diagnostic products.
|
| |
|
|
|
|
Dr Nicky Thelwell
Nicky Thelwell has 8 years experience in the Biotechnology Industry, having worked for Oswel/Eurogentec before joining DxS. Nicky has a proven track record in technology development and evaluation. She has previously worked with customers to develop numerous diagnostic assays. Her background in both research and industry, and her knowledge of diagnostic development process make her ideally suited for the role of Product Development Manager.
|
| |
|
|
|
|
Dr Steven Wolfenden
Steven has gained technical experience in the pharmaceutical industry working in the areas of dry powder inhalers and sterile products at Ashton Pharmaceuticals Limited (APL). More recently he has been one of two project managers at APL responsible for new product introduction at their manufacturing and packing facility. As a project manager at APL, Steven was the primary customer interface between the project team and the client, in the areas of manufacture for clinical trials, solid dose and sterile products.
|
| |
|
|